Clinical Guest Contributors

  1. It's A Fact: Sharing Clinical Trial Results With Participants Builds Trust 5/14/2026

    CISCRP experts share results from their annual Perceptions & Insights Study showing that patients continue to place a high value on receiving both individual and overall study results.

  2. When AI Agents Start Researching Trials On Behalf Of Patients, What Happens? 5/13/2026

    Right now, patients are using AI agents to find clinical trials. But soon enough, these AI tools will be doing it on their own and feeding patients the results. Recruitment expert Ross Jackson discusses this shift and what it will mean for sponsors.

  3. The U.S. Clinical Trial Recruiting Pipeline Report – May 2026 5/12/2026

    This WhichTrial report breaks down which drug trials are growing the most and the least, drugs that are no longer being studied, and new drugs to the clinic from March 7 to May 1, 2026. 

  4. Safe And Scalable AI Deployment For Clinical Trials 5/11/2026

    When life sciences organizations lack a structured, evidence-based methodology for scaling AI tools safely and effectively, they put clinical development at risk. Partha Anbil and Partha Khot team up to share a practical approach to its implementation.

  5. Small Biotech Survival: Navigating Risk And Capital Scarcity With AI 5/8/2026

    Maxine Opperman discusses the challenge and the necessity of small biotech's using AI, citing its pros, cons, and strategies for use.

  6. 5 Critical Risks With The FDA's Real-Time Trial Monitoring 5/8/2026

    Life science legal experts Kimberly Chew and Odette Hauke cover the FDA proof-of-concept real-time clinical trials (RTCTs) and expose five major issues that must be addressed before the pilot expands.

  7. Executive Order For Psychedelics 5/8/2026

    We caught up with Joseph Tucker, Ph.D., CEO of Enveric Biosciences, to discuss the executive order for psychedelics.

  8. Aligning AI Use Clinical Trials With FDA And EMA Expectations 5/7/2026

    For any trial conducted in the EU/EEA, regulators want to know that AI used across clinical trial planning, conduct, and analysis is transparent, controlled, and fit for purpose. Jessica Cordes explains how even U.S.-based teams must meet EMA expectations.

  9. Precision Medicine Needs Better Infrastructure — And We Already Have The Models For It 5/6/2026

    Standard methods for evaluating clinical trial representativeness perform poorly when the trial population differs from the broader disease population in a patient registry. June Cha, Ph.D., MPH, explains how the right metrics can make a difference.

  10. Here's How FDA's Accelerated Approval Pathway Has Evolved Since '24 5/5/2026

    FDA's accelerated approval guidance kicked off a rebalancing of new drug approval pathways. Since its 2024 release, the agency has been building on it in a few key areas.